Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models
- 29 June 2006
- journal article
- research article
- Published by Elsevier in NeuroToxicology
- Vol. 27 (5) , 807-815
- https://doi.org/10.1016/j.neuro.2006.06.006
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The ubiquitin–proteasome system and neurodegenerative disordersEssays in Biochemistry, 2005
- Serofendic acid prevents 6‐hydroxydopamine‐induced nigral neurodegeneration and drug‐induced rotational asymmetry in hemi‐parkinsonian ratsJournal of Neurochemistry, 2005
- MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASEAnnual Review of Neuroscience, 2005
- Ubiquitin–proteasome system and Parkinson's diseasesExperimental Neurology, 2004
- Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stressJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2004
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004
- Molecular Pathways of Neurodegeneration in Parkinson's DiseaseScience, 2003
- Parkinson's DiseaseNeuron, 2003
- Parkin Protects against the Toxicity Associated with Mutant α-SynucleinNeuron, 2002
- Proteasome inhibition causes nigral degeneration with inclusion bodies in ratsNeuroReport, 2002